Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia

Grzegorz Porebski; Alicja Dziadowiec

doi:10.5114/pja.2024.135546

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2024
vol. 11

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Opis przypadku

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia

Grzegorz Porebski

¹

,

Alicja Dziadowiec

^{1, 2}

Department of Clinical and Environmental Allergology, Jagiellonian University, Medical College, Krakow, Poland

Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland

Alergologia Polska – Polish Journal of Allergology 2024; 11, 1: 73–75

DOI: https://doi.org/10.5114/pja.2024.135546

Data publikacji online: 2024/02/20

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

In this report, we describe a patient with a delayed cutaneous hypersensitivity reaction to evolocumab, a human monoclonal antibody directed against the serine protease proprotein convertase subtilisin/kexin type 9 used to reduce low-density lipoprotein concentrations in the treatment of familial hypercholesterolaemia. The patient developed erythematous exfoliative lesions on the skin after the third administration of evolocumab. After each of the next three consecutive doses, the lesions worsened for 24 h, persisted for approximately 7 days, and then went into partial remission. Discontinuation of evolocumab resulted in a complete remission. Hypersensitivity reactions induced by biological drugs are becoming an increasing problem, but knowledge of these reactions is still limited. Our case report convincingly demonstrates the causal relationship between repeated drug exposure and the development and exacerbation of clinical symptoms. It also highlights a dilemma in the management of such clinical situations: the ‘treat-through’ strategy versus withdrawal of vital treatment.

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia

Grzegorz Porebski 1 , Alicja Dziadowiec 1, 2

Grzegorz Porebski

¹

,

Alicja Dziadowiec

^{1, 2}